Tumor-Associated Hypoglycemia

  • Scott Wadler


Tumor-associated hypoglycemia is an uncommon complication of neoplastic proliferation. Because of its rarity, it is commonly overlooked and, when recognized, may pose numerous difficulties in diagnosis and management. Because the symptoms are nonspecific, it may initially be difficult to distinguish alteration of mental status due to “glucose starvation” from that produced by other metabolic or infectious etiologies in the patient with advanced cancer. When the problem has been identified, it then becomes necessary to distinguish tumor-associated hypoglycemia from more commonly encountered causes of hypoglycemia, such as postabsorptive (reactive) hypoglycemia and iatrogenic hypoglycemia. Finally, when the process has been identified as paraneoplastic, it then becomes necessary to distinguish between islet-cell carcinoma and tumors that do not produce insulin. This chapter is intended to assist the practitioner in identifying and managing paraneoplastic complications that result from tumor-induced hypoglycemia.


Plasma Glucose Level Pancreatic Polypeptide Altered Mental Status Adrenocortical Carcinoma Immunoreactive Insulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fajans SS, Floyd JC: Fasting hypoglycemia in adults. N Eng J Med 294: 766–772, 1976.CrossRefGoogle Scholar
  2. 2.
    Fajans SS, Floyd JC: Diagnosis and medical management of insulinomas. Annu Rev Med 30: 313–329, 1979.PubMedCrossRefGoogle Scholar
  3. 3.
    Turner RC, Morris PJ, Lee EC, Harris EA: Localization of insulinomas. Lancet 1: 515–518, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    Kahn RC: The riddle of tumor hypoglycemia revisited. Clin Endocrinol Metab 9: 335–360, 1980.PubMedCrossRefGoogle Scholar

Selected Readings

  1. Gale E: Hypoglycemia. Clin Endocrinol Metab 9: 461–477, 1980.Google Scholar
  2. Gorden P, Henricks CM, Kahn CR, Megyesi K. Roth J: Hypoglycemia associated wtih non-islet-cell tumor and insulin-like growth factors. N Engl J Med 305: 1452–1455, 1981.PubMedCrossRefGoogle Scholar
  3. Immerman SC, Sener FF, Khandakar JD: Causes and evaluation of tumor-induced hypoglycemia. Arch Surg 117: 905–908, 1982.PubMedCrossRefGoogle Scholar
  4. Megyesi K, Kahn CR, Roth J, et al: Hypoglycemia in association with extrapancreatic tumors: Demonstration of elevated plama NSILA-S by a new radioreceptor assay. J Clin Endocrinol Metab 38: 931–936, 1974.PubMedCrossRefGoogle Scholar
  5. Schein PS: Chemotherapeutic management of the hormone-secreting endocrine malignancies. Cancer 30: 1616–1626, 1972.PubMedCrossRefGoogle Scholar
  6. Service FJ, Dale AJD, Elvepack LR, Tiang NS: Insulinoma: Clinical and diagnostic features in sixty consecutive cases. Mayo Clin Proc 51: 417–429, 1976.PubMedGoogle Scholar
  7. Turner RC, Heding LG: Plasma proinsulin, C-peptide and insulin in diagnostic supression tests of insulinomas. Diabetologia 13: 571–577, 1977.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Scott Wadler
    • 1
  1. 1.Department of OncologyAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA

Personalised recommendations